Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience

This article was originally published in The Pink Sheet Daily

Executive Summary

A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.

You may also be interested in...



Generic Industry Once Again Must Get To Know New US FDA Office Director

Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.

US FDA Again Looks Outside Generic Drugs Office For New Director

Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.

'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Implementer of many drug review changes will leave in January after nearly 32 years of public service.

Related Content

Topics

UsernamePublicRestriction

Register

PS075414

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel